Table 1.
Range of Point Estimates of Percentage All-Cause Mortality at Days 14 and 28
| Sponsor (Analysis Population) |
VABP | Ventilated HABP |
Nonventilated HABP |
|---|---|---|---|
| Study day 14 | |||
| Shionogi (AT) | 6.3%–9.8% | 9.5%–14.9% | 3.1%–9.6% |
| Pfizer (AT) | 7.9% | 6.5% | 6.1% |
| Theravance (AT) | 16.8% | 16.3% | 13.0% |
| Barcelona (AT-ICU) | 19.8% | 24.0% | 17.4% |
| Study day 28 | |||
| Shionogi (AT) | 10.2%–19.9% | 20.8%–23.2% | 11.0%–13.5% |
| Pfizer (AT) | 12.6% | 15.2% | 9.8% |
| Theravance (AT) | 26.3% | 30.2% | 18.8% |
| Barcelona (AT-ICU) | 27.0% | 39.4% | 21.7% |
Abbreviations: AT, all-treated patient analysis population; HABP, hospital-acquired bacterial pneumonia; ICU, intensive care unit; VABP, ventilator-associated bacterial pneumonia.